Cabazitaxel: A novel drug for hormone-refractory prostate cancer

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 6, 2013, Pages 915-920

  Malhotra, Manav ^a   Dhingra, Richa ^a   Sharma, Tina ^a   Deep, Aakash ^b   Narasimhan, Balasubramanian ^b   Phogat, Priyanka ^c   Sharma, Prabodh Chander ^d  

^a ISF COLLEGE OF PHARMACY   (India)

^b MAHARSHI DAYANAND UNIVERSITY   (India)

^c Hindu College   (India)

^d KURUKSHETRA UNIVERSITY   (India)

Author keywords

Cabazitaxel; Jevtana; Prostate cancer; Sanofi aventis; Taxanes; XRP 6258

Indexed keywords

ATAZANAVIR; CABAZITAXEL; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 2C8; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MITOXANTRONE; NEFAZODONE; NELFINAVIR; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RANITIDINE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; SAQUINAVIR; TELITHROMYCIN; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BRONCHOSPASM; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); COUGHING; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; DYSURIA; ELECTROLYTE DISTURBANCE; ERYTHEMA; FEVER; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEMATURIA; HUMAN; HYPOTENSION; KIDNEY FAILURE; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OBSTRUCTIVE UROPATHY; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RASH; SEPSIS; SURVIVAL; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TAXOIDS; TUBULIN MODULATORS;

EID: 84876712080     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313060011     Document Type: Article

References (43)

1. Paller, C.J.; Antonarakis, E.S. Cabazitaxel: a novel second-line treatment for metastatic castration resistant prostate cancer. Drug Des. Devel. Ther., 2011, 5, 117-124.
2. Yap, T.A.; Carden, C.P.; Attard, G. Targeting CYP17: established and novel approaches in prostate cancer. Curr. Opin. Pharmacol., 2008, 8, 449-457.
3. Pivot, X.; Koralewski, P.; Hidalgo, J.L. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol., 2008, 19, 1547-1552.
4. Malik, Z.I. Cabazitaxel: Evidence and clinical experience. Br. J. Med. Surg. Urol., 2011, 4, 14-20.
5. Dumontet, C.; Sikic, B.I. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J. Clin. Oncol., 1999, 17, 1061-1070.
6. Beltran, H.; Beer, T.M.; Carducci, M.A.; Bono, J.D.; Martin, Gleave.; Hussain, M.; Kelly, W.K.; Saad, F.; Sternberg, C.; Tagawa, S.T.; Tannock, I.F. New treatment options for patients with metastatic castration-resistant prostate cancer. Eur. Urol., 2011, 60, 279-290.
7. Brawley, O.W.; Parnes, H. Prostate cancer prevention trials in the USA. Eur. J. Cancer, 2000, 36, 1312-1315.
8. Filella, X.; Molina, R.; Ballesta, A.M.; Gil, M.J.; Allepuz, C.; Rioja, L.A. Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study. Eur. J. Cancer, 1996, 32, 1125-1128.
9. Bono, J.S.D.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, Liji.; Roessner, M.; Gupta, S.; Sartor, A.O. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet., 2010, 376, 1147-1154.
10. Anna, Lydon. Cabazitaxel side effects: Prevention and management. Br. J. Med. Surg. Urol., 2011, 4, 21-27
11. Bruijn, P.D.; Graan, A.J.M.D, Nieuweboer, A.; Mathijssen, R.H.J.; Lam, M.H, Wit, R.D, Wiemer, E.A.C.; Loos, W.J. Quantification of Cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding. J. Pharm. Biomed. Anal., 2012, 59, 117-122.
12. Liu, K.K.C.; Sakya, S.M.; O'Donnell, C.J.; Flick, A.C.; Ding, H.X. Synthetic approaches to the 2010 new drugs Bioorg. Med. Chem., 2012, 20, 1155-1174.
13. Matthew, D.; Galsky, A.D.; Peter, K.; William K.O. Cabazitaxel. Nat. Rev, Drug Discov., 2010, 9, 677-678.
14. Zhao, J.; Bane, S.; Snyder, J.P.; Hu, H.; Mukherjee, K.; Slebodnick, C.; Kingston, D.G.I. Design and synthesis of simplified taxol analogs based on the T-Taxol bioactive conformation Bioorg. Med. Chem., 2011, 19, 7664-7678.
15. Pal, S.K.; Twardowski, P.; Sartor, O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin. Interv. Aging., 2010, 5, 395-402.
16. Antonarakis, E.S.; Armstrong, A.J. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis., 2011, 14, 192-205.
17. Wilkes, G.M. Cabazitaxel, a taxane for men with hormonerefractory metastatic prostate cancer. Oncology, 2010, 24, 46-48.
18. Agarwal N, Sonpavde G, Sartor O. Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol., 2011, 7, 15-24.
19. Villanueva, C.; Awada, A.; Campone, M.; Machiels, J.P.; Besse, T.; Magherini, E.; Dubin, F.; Semiond, D.; Pivot, X. A multicentre dose-escalating study of cabazitaxel in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur. J. Cancer, 2011, 47, 1037-45.
20. Villanueva, C.; Bazan, F.; Kim, S.; Demarchi, M.; Chaigneau, L.; Thiery-Vuillemin, A.; Nguyen, T.; Cals, L.; Dobi, E.; Pivot, X. Cabazitaxel: a novel microtubule inhibitor. Drugs, 2011, 71, 1251-1258.
21. Sandra, M.S.; Joseph, C.A. Neuropathy Associated with microtubule inhibitors: Diagnosis, Incidence, and Management. Clin. Adv. Hematol. Oncol., 2008, 6, 455-467.
22. Cisternino, S.; Bourasset, F.; Archimbaud, Y.; Semiond, D.; Sanderink, G.; Scherrmann, J.M. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of Pglycoprotein at the blood-brain barrier in mice and rats. Br. J. Pharmacol., 2003, 138, 1367-1375.
23. Shore, N.; Mason, M.; Reijke, T.M. New developments in castrateresistant prostate cancer. B.J.U. Int., 2012, 109, 22-32.
24. Marech, I.; Vacca, A.; Ranieri, G.; Gnoni, A.; Dammacco, F. Novel strategies in the treatment of castration-resistant prostate cancer. Int. J. Oncol., 2012, 40, 1313-1320.
25. Shabafrouz K.; Bauer J.; Berthold D.R. New drugs at the horizon for men with prostate cancer. Rev. Med. Suisse, 2010, 6, 1057-1058.
26. Di Lorenzo G.; Buonerba C.; Autorino R.; De Placido, S.; Sternberg, C. N Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs, 2010, 70, 983-1000.
27. Petrylak, D.P. Current clinical trials in castrate-resistant prostate cancer. Curr. Urol. Rep., 2011, 12, 173-179.
28. Engels, F.K.; Sparreboom, A.; Malthotra, V.J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. J. Br. Cancer, 2005, 93, 173-177.
29. Brooks, T.; Minderman, H.; Loughlin, K.L. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther., 2003, 2, 1195-1205.
30. Gelmon, K.A.; Latreille, J.; Tolcher, A. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J. Clin. Oncol., 2000, 18, 4098-4108.
31. Sessa C, Cuvier C, Caldiera S, et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann. Oncol., 2002, 13, 1140-1150.
32. Galsky, M.D.; Dritselis, A.; Kirkpatrick, P.; OH, W.K. Cabazitaxel. Nat. Rev. Drug Discov., 2010, 9, 677-678.
33. Martin, J.M.; Supiot, S.; Berthold, D.R. Pharmacotherapeutic management of locally advanced prostate cancer: current status. Drugs., 2011, 71, 1019-1041.
34. Agarwal, N.; Hutson, T.E.; Vogelzang, N.J.; Sonpavde G.; Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol., 2010, 6, 665-679.
35. Antonarakis, E.S.; Drake, C.G. Current status of immunological therapies for prostate cancer. Curr. Opin Urol. 2010, 20, 241-246.
36. Danila, D.C.; Morris, M.J.; De Bono, J.S.; Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 2010, 58, 1496-1501.
37. Dorff, T.B.; Quinn, D.I. Cabazitaxel in prostate cancer: stretching a string. Lancet, 2010, 376, 1119-1120.
38. De Coster, R.; Wouters, W.; Bruynseels, J. P450-dependent enzymes as targets for prostate cancer therapy. J. Steroid Biochem. Molec. Biol. 1996, 56, 133-143.
39. Bouchet, B.P.; Galmarini, C.M. Cabazitaxel, a new taxane with favorable properties. Drugs Today, 2010, 46, 735-42.
40. Jilani, A.; George, E.; Adler, A.I. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. Lancet Oncol., 2012, 13, 573-574.
41. Madan, R.A.; Mohebtash, M.; Arlen, P.M. Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol., 2010, 28, 2550-2555.
42. Mostaghel, E.A.; Montgomery, B.; Nelson, P.S. Castrationresistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol. Oncol., 2009, 27, 251-257.
43. Alcaraz, A.; Medina, R.; Maroto, P.; Climent, M.A.; Castellano, D.; Carles, J. Castration-resistant prostate cancer: where are we going. Actas Urol. Esp., 2012, 36, 367-74.